Switch to:
More From Other Websites
Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10 Feb 04 2016
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study Feb 02 2016
Exelixis Rises on Positive Late-Stage Trial Results Feb 01 2016
Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of... Feb 01 2016
Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question Feb 01 2016
Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of... Feb 01 2016
Exelixis's Cabozantinib Granted Priority Review in the U.S. Jan 29 2016
Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for... Jan 28 2016
Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority... Jan 28 2016
Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Jan 27 2016
[video]'Mad Money' Lightning Round: Move on From Broadcom Jan 20 2016
Exelixis upgraded by Leerink Partners Jan 19 2016
Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a... Jan 11 2016
The Zacks Analyst Blog Highlights: AbbVie, Amgen, Ligand Pharmaceuticals, Revance Therapeutics and... Jan 08 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK